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Abstract
Background The aim of this study is to report the experience with conversion surgery from six Gruppo Italiano Ricerca 
Cancro Gastrico (GIRCG) centers, focusing our analysis on factors affecting survival and the risk of recurrence.
Methods A retrospective, multicenter cohort study was performed in patients who had undergone conversion gastrectomy 
between 2005 and 2017. Data were extracted from a GIRCG database including all metastatic gastric cancer patients submit-
ted to surgery. Only stage IV unresectable tumors/metastases which became resectable after chemotherapy were included 
in this analysis.
Results Forty-five resected M1 patients were included in the analysis. Reasons for being deemed unresectable at diagnosis 
were peritoneal involvement (PCI > 6) (n = 38, 84.4%), distant metastatic nodes (n = 3, 6.6%) and extensive liver involvement 
(n = 4, 8.8%). Median follow-up was 25 months (IQR 9-50). Median overall survival from surgery was 15 months and 1-, 
3- and 5-year survivals were 57.2, 36.1 and 24%, respectively. Median progression-free survival was 12 months with 1- and 
3-year survival of 46.4 and 33.9%, respectively. At cox regression analysis the only independent prognostic factor for OS was 
the presence of more than one type of metastasis (HR 4.41, 95% CI 1.72–11.3, p = 0.002). A positive microscopic resection 
margin was the only risk factor for recurrence (HR 5.72, 95% CI 1.04–31.4, p = 0.045).
Conclusions Unresectable stage IV GC patients could benefit from radical surgery after chemotherapy and achieve long 
survivals. The main prognostic factor for these patients was the presence of more than one type of extra-gastric metastatic 
involvement.
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Introduction
Stage IV gastric cancer carries a poor prognosis. As per cur-
rent guidelines [1, 2] the only therapeutic option for these 
patients could be palliative chemotherapy which may offer 
survivals up to 24 months [3]. However, there is growing 
literature reporting long survivals in those cases (stage IV 
gastric cancer) who responded to palliative chemotherapy 
and were subsequently submitted to gastrectomy [4–11]. In 
particular, this multimodal treatment, which was defined 
as conversion surgery, could be associated with significant 
improved survivals of more than 40 months when R0 resec-
tion could have been achieved [5, 11].
Still, literature about conversion surgery is scarce and 
studies are usually characterized by limited sample sizes and 
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different definitions [7, 12]. In addition, to date, all but one 
study was performed on a cohort from a western center [7].
With this paper, we aim to report the experience of six 
GIRCG centers with conversion surgery, focusing our analy-
sis on factors affecting survival and the risk of recurrence.
Materials and methods
Study design
A retrospective, multicenter cohort study was performed 
in patients who had undergone conversion gastrectomy 
April 1, 2005 and January 1, 2017 in 6 centers belonging to 
Gruppo Italiano Ricerca Cancro Gastrico (GIRCG) centers. 
Data were extracted from a GIRCG database including all 
metastatic gastric cancer patients submitted to surgery. Only 
stage IV GC which became resectable, (showing partial or 
complete response) after chemotherapy were included in this 
analysis.
Definitions
Patients’ diagnosis, treatment and perioperative care were 
performed as recommended by GIRCG guidelines in all 
participating centers [2]. Conversion surgery was defined 
as a surgical treatment aiming at R0 resection for tumors 
that were deemed unresectable before chemotherapy. As 
per study protocol, the definition of an unresectable tumor/
metastasis before chemotherapy was based on technical and 
oncological reasons and included: peritoneal cancer index 
(PCI) (as defined by Sugarbaker et al. [13]) > 6, bilobar 
hepatic metastases, nodal involvement outside D1-3 stations, 
technically unresectable metastases.
Staging laparoscopy was performed in all patients before 
chemotherapy. The re-assessment for resectability was based 
on the imaging performed during treatment at 3–6 months. 
Surgery was proposed only to those patients in whom gas-
trectomy and associated resections could have been poten-
tially radical. In particular, the peritoneal involvement was 
considered for treatment only in case of PCI < 6 at explora-
tion after palliative chemotherapy.
All specimens were histopathologically classified accord-
ing to Lauren’s microscopic criteria [14]. Tumor stage was 
presented as indicated by the Union for International Can-
cer Control (UICC)/American Joint Committee on Cancer 
(AJCC) [15]. All cases were also grouped as proposed by 
Yoshida et al. [16].
Variables
Baseline characteristics collected included sex, age, Ameri-
can Society of Anaesthesiologists (ASA) score, type f 
preoperative chemo- and/or radiotherapy, preoperative stag-
ing (pTNM). Operative variables collected included type 
of procedure and lymphadenectomy, additional resections, 
intraoperative multimodal treatments and number of lym-
phnode harvested. Tumor-related variables included pathol-
ogy stage (pTNM), resection margin status, tumor regression 
grade, Lauren’s histotype and grading. Complications were 
all collected up to the day of discharge and graded according 
to Clavien et al. [17]. Progression-free survival (PFS) and 
overall survival(OS) were the primary outcome measures.
Statistical analysis
Continuous data were presented as median and interquartile 
range (IQR). The Kaplan–Meier curve was used to calculate 
survival rates. OS was calculated as the time between both 
diagnosis and surgery and death/last follow-up. PFS was 
defined as the time between surgery and the first evidence 
of disease recurrence/progression and was calculated for all 
patients excluding R2 resections. Cox regression was per-
formed to find independent factors affecting survival after 
surgery. Hazard ratios (HR) and 95% confidence intervals 
(95% CI) were calculated when required. Only variables 
with p < 0.050 at univariate analysis were entered in mul-
tivariable analyses in a stepwise manner. Follow-up was 
calculated as recommended elsewhere [18]. Analyses were 
performed with MedCalc Statistical Software (MedCalc 
Software bvba, Ostend, Belgium).
Results
In total, 287 stage IV GC patients were screened, of whom 
242 were excluded for reasons (193 had no preoperative 
chemotherapy, 38 had preoperative chemotherapy for tech-
nically resectable disease, 11 had no details about preop-
erative period), leaving 45 patients for analysis. Patients’ 
characteristics at diagnosis are presented in Table 1. Reasons 
for being deemed unresectable at diagnosis were peritoneal 
involvement (n = 38, 84.4%), distant metastatic nodes (n = 3, 
6.6%) and extensive liver involvement (n = 4, 8.8%).
Operative variables are shown in Table 2. In 33 (73.3%) 
cases peritoneal resections were required while in 3 these 
were not performed due to the extent of the disease. Two 
patients with peritoneal involvement had complete response 
after palliative chemotherapy and peritonectomy procedures 
were not performed as no residual disease was found. Post-
operative complications occurred in 18 (40%) patients; and 
they had a Clavien-Dindo grade above 2 in 14 cases (31.1%). 
Tumor-related variables are presented in Table 3.
Median follow-up was 25 months (IQR 9-50). Median 
overall survival was 15 months and 1-, 3- and 5-year surviv-
als were 57.2, 36.1 and 24%, respectively (Fig. 1). Median 
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OS calculated from diagnosis of GC was 20.6 months with 
1-, 3- and 5-year survival of 78.2, 38.6 and 26.5%. Median 
PFS was 12 months with 1- and 3-year survival of 46.4 and 
33.9%, respectively (Fig. 2).
At cox regression analysis the only independent prognos-
tic factor for OS was the presence of more than one type of 
Table 1  Patients’ characteristics at diagnosis
Age—median (IQR) 54 (48–61)
Female, n (%) 18 (40)
ASA > 2, n (%) 2 (4.1)
Tumor site, n (%)
 Upper third 6 (13.3)
 Middle third 12 (26.7)

















Types of palliative chemotherapy
 Cisplatin plus fluoropyrimidine 20 (44.4)
 Epirubicin and Cisplatin plus fluoropyrimidine 9 (20)
 Docetaxel and Oxaliplatin plus fluoropyrimidine 9 (20)
 Other types 7 (15.5)
Table 2  Operative variables
HIPEC hyperthermic intraperitoneal chemotherapy
Type of procedure, n (%)
 Total gastrectomy 33 (73.3)
 Subtotal gastrectomy 12 (26.7)




Additional procedure, n (%)
 None 23 (51.1)
 >1 additional resection 7 (15.5)
 Colectomy 6 (13.3)
 Splenectomy 5 (11.1)
 Distal pancreatectomy 2 (4.4)
 Small bowel resection 1 (2.2)
 Distal splenopancreatectomy 1 (2.2)
 HIPEC, n (%) 23 (51.1)
Table 3  Pathology variables
TRG tumor regression grade





















Lymphnodes harvested n (%)





 > 75 1 (2.2)




 Not specified 21 (42.8)








 Not specified 7 (15.5)
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metastasis (HR 4.41, 95% CI 1.72–11.3, p = 0.002) (Table 4) 
(Fig. 3). A positive microscopic resection margin was the 
only risk factor for recurrence (HR 5.72, 95% CI 1.04–31.4, 
p = 0.045) (Table 5).
Discussion
Stage IV unresectable gastric cancer patients could benefit 
from surgery, which may offer prolonged survival.
More than 20  years ago, first, Nakajima et  al. [8] 
described similar findings. Authors showed that unresectable 
Fig. 1  Kaplan-Meier curve of 
overall survival for the whole 
cohort
Fig. 2  Kaplan-Meier curve of 
progression free survival
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HR (95% CI) P HR (95% CI) p
Age* 45 1.01 (0.96–1.05) 0.467
Sex
 Male 27 1.00 1.000
 Female 18 0.75 (0.31–1.84) 0.536
ASA 43 1.00 1.000
 ≤ 2 2 2.76 (0.63–12.1) 0.180
 > 2
cT
 cT3 9 1.00 0.000
 cT4 33 1.91 (0.56–6.49) 0.305
cN
 cN0 10 1.00 1.000
 cN+ 35 1.29 (0.67–2.51) 0.444
Type of lymphadenectomy
 D1 4 1.00 1.000
 D2 19 0.46 (0.12–1.72) 0.253
 D3 22 0.27 (0.07–1.07) 0.065
Additional resection
 No 23 1.00 1.000
 Yes 22 1.35 (0.58–3.13) 0.485
HIPEC
 No 22 1.00 1.000
 Yes 23 0.85 (0.37–1.91) 0.689
Postoperative complications
 No 27 1.00 1.000
 Yes 18 0.80 (0.33–1.94) 0.622
Lymphnode harvested* 45 0.97 (0.93–1.01) 0.108
Grading
 G2 4 1.00 1.000
 G3 34 1.04 (0.30–3.56) 0.949
Lauren’s hystotype
 Intestinal 11 1.00 1.000
 Diffuse 29 0.87 (0.37–2.32) 0.877
 Mixed 4 4.16 (1.01–17.2) 0.049
pT
 pT < 4 17 1.00 1.000
 pT4a-b) 28 1.5 (0.62–3.62) 0.365
pN
 N0 3 1.00 1.000
 N1 5 0.63 (0.08–4.51) 0.649
 N2 7 1.39 (0.23–8.32) 0.721
 N3a 10 2.32 (0.48–11.3) 0.295
 N3b 17 1.11 (0.23–5.35) 0.897
Radical treatment
 R0 30 1.00 1.000
 R1 7 0.93 (0.21–4.09) 0.922
 R2 8 2.24 (0.67–7.54) 0.194
Type of metastasis
 Single site, non-peritoneal 5 1.00 1.000
 Peritoneal 29 4.37 (0.57–33.1) 0.156
 > 1 type 11 16.0 (1.91–134.7) 0.011 4.41 (1.72–11.3) 0.002
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GC could become resectable after intensive chemotherapy 
and found that long survivors were only in the group of 
patients who could have radical surgery after chemotherapy.
Since then, an increasing number of researchers tried to 
investigate the role of the combination of preoperative/pal-
liative/induction chemotherapy followed by surgery in the 
treatment of advanced unresectable gastric cancer. Currently, 
literature demonstrated that so-called conversion surgery for 
unresectable stage III or stage IV gastric cancer was asso-
ciated with longer survival than chemotherapy alone. The 
most recent studies on stage III/IV unresectable patients 
undergoing conversion surgery reported survivals ranging 
from 37 to 56 months [4, 5, 7, 9–11, 19–22].
The survival reported in our study is lower than those 
reported by others and this could be ascribed to the inclu-
sion criteria we selected for our analysis. As such, our study 
population included only part of stage IV patients who had 
undergone chemotherapy plus surgery. In particular, we 
excluded from this study all stage IV GC patients who had 
chemotherapy plus surgery with PCI ≤ 6, unilobar techni-
cally resectable hepatic metastasis, only positive cytology or 
positive nodal metastases in D3 stations. As a consequence, 
our inclusion criteria identified a selected population com-
posed mainly by Yoshida type 3 and 4 patients for whom 
an extraordinary response to chemotherapy could have led 
to the complete resection of the primary tumor and the 
peritoneal, nodal and liver metastases. As it has been high-
lighted by Yoshida et al. [16] and Yamaguchi et al. [11], 
peritoneal metastases in these cases may be technically 
resected but they often recur. In our study, a sub-population 
of Yoshida type 3 (macroscopic peritoneal dissemination 
without other organs involvement) patients showed unex-
pected survivals, being more than 35% alive 3 years after 
surgery. We believe that the results presented in this study 
may recommend not to exclude surgery a priori in selected 
advanced cases of stage IV GC.
In our analysis we found that more than one type of 
metastasis significantly affect prognosis. Similar findings 
were found by other authors [5, 10, 22], who showed that 
more than one non-curative factors were associated with a 
poor prognosis in unresectable GC patients. In light of those 
findings, it might be suggested not to proceed with surgery 
in those patients who have more than one district involved 
by metastases. Still, further data are required to confirm this 
hypothesis.
To date, the highest level of evidence about stage IV 
gastric cancer and the potential benefit of surgery in these 
patients is available thanks to the REGATTA trial [23]. This 
study showed that stage IV patients can benefit from surgery 
in terms of survival only when this is radical. Recently, these 
conclusions were also reached by the analyses of retrospec-
tive series of stage IV/unresectable patients undergoing 
Table 4  (continued) *Analyzed as continuous variables
HIPEC hyperthermic intraperitoneal chemotherapy
Fig. 3  Kaplan-Meier curves of 
overall survival according to the 
type of extra-gastric involve-
ment
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Table 5  Cox regression analysis 
of disease-free survival
*Analyzed as continuous variables, § no cases of recurrence, calculated on 34 patients (of 37 R0-R1 
patients, 3 did not have details about recurrence), HIPEC hyperthermic intraperitoneal chemotherapy
Variable n PFS°
Univariate Multivariate
HR (95% CI) P HR (95% CI) p
Age* 34 0.99 (0.95–1.04) 0.744
Sex
 Male 21 1.00 1.000
 Female 13 0.93 (0.38–2.29) 0.871
ASA
 ≤ 2 33 1.00 1.000
 > 2 1 2.34 (0.29–18.4) 0.421
cT
 cT3 7 1.00 1.000
 cT4) 25 2.33 (0.51–10.6) 0.275
cN (cN0 vs cN +) 0.65 (0.31–1.36) 0.258
Type of lymphadenectomy
 D1 3 § 0.069
 D2 13 2.37 (0.93–6.02) 1.000
 D3 18 1.00
Additional resection
 No 16 1.00 1.000
 Yes 18 0.53 (0.20–1.34) 0.187
HIPEC
 No 15 1.00 1.000
 Yes 19 0.69 (0.26–1.84) 0.469
Postoperative complications
 No 24 1.00 1.000
 Yes 10 2.53 (0.16–1.20) 0.112
Lymphnode harvested* 45 1.01 (0.97–1.06) 0.466
Grading
 G2 4 1.00 1.000
 G3 24 2.99 (0.39–22.7) 0.292
Lauren’s hystotype
 Intestinal 10 1.00 1.000
 Diffuse 19 2.00 (0.63–6.39) 0.244
 Mixed 4 4.38 (0.95–20.2) 0.059
pT
 pT < 4 12 1.00 1.000
 pT4a-b 21 2.19 (0.77–6.22) 0.141
pN
 N0 3 § 0.594
 N1 2 §
 N2 5 0.66 (0.14–3.00) 0.438
 N3a 8 1.49 (0.54–4.12)
 N3b 14 1.00 1.000
Radical treatment
 R0 30 1.00 1.000 5.72 (1.04–31.4) 0.045
 R1 4 5.72 (1.04–31.4) 0.045
Type of metastasis
 Single site, non-peritoneal 5 1.00 1.000
 Peritoneal 21 0.90 (0.19–4.16) 0.895
 > 1 type 8 3.29 (0.64–16.8) 0.153
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induction chemotherapy followed by surgery [5, 11]. Yama-
guchi et al. [11] in their multi institutional study on 77 stage 
IV GC patients who had undergone conversion surgery 
found that median survival was 41.3 for R0 patients while it 
was 21.2 months for R1-2.
Our study, which is the largest in the western literature, 
confirmed that R0 conversion surgery was associated with a 
significantly longer PFS than R1 resections. In our opinion, 
this latter finding further highlights the importance of radi-
cal surgery in the attempt to improve survival in metastatic 
GC patients.
Current literature about conversion surgery lacks of 
standardized definitions as it was also highlighted by 
Terashima [12]: the criteria for initial determination of onco-
logically unresectable or determination of resectability post-
chemotherapy are heterogeneous among studies and results 
should always be interpreted in light of these differences. An 
effort from the scientific community would be required to 
find common definitions, and thus, reliable results in future 
studies.
The main limitation of this study is that the long study 
period covers several advances in oncology and, thus, in the 
chemotherapy regimens adopted. This resulted in a hetero-
geneous population in terms of type of chemotherapy used 
which made it difficult to understand the real impact of a 
regimen in the achievement of complete/partial response.
In conclusion, conversion gastrectomy is a treatment 
option for selected patients with stage IV GC. The main 
prognostic factor for these patients was the presence of more 
than one type of extra-gastric metastatic involvement. A rad-
ical procedure was significantly associated with a reduced 
risk of recurrence.
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